Vaughan K - Search Results

1

Interplay of hydrogen bonding and other molecular interactions in determining the crystal packing of a series of anti-beta-ketoarylhydrazones.

Bertolasi V V, Gilli P, Ferretti V V, Gilli G, Vaughan K, Jollimore JV. Bertolasi V V, et al. Among authors: vaughan k. Acta Crystallogr B. 1999 Dec 1;55(Pt 6):994-1004. doi: 10.1107/s0108768199008435. Acta Crystallogr B. 1999. PMID: 10927442

2

1-(p-carbamoylphenyl)-3,3-dimethyl-triazene, an antitumour agent.

Bullerwell WL, MacGillivray LR, Zaworotko MJ, Vaughan K, Wilman DE. Bullerwell WL, et al. Among authors: vaughan k. Acta Crystallogr C. 1995 Dec 15;51 ( Pt 12):2624-7. doi: 10.1107/s0108270195008419. Acta Crystallogr C. 1995. PMID: 8588860

3

Triazene metabolism. VI. 3-Azidomethyl-3-alkyl-1-aryltriazenes, a new class of anti-tumour triazene with potential pro-drug applications.

Vaughan K, Nicholas G, Singer RD, Roy M, Gibson NW. Vaughan K, et al. Anticancer Drug Des. 1987 Dec;2(3):279-87. Anticancer Drug Des. 1987. PMID: 3449091

4

Triazene metabolism. V. Chemical and biological properties of N,N-bis-[(1-aryl-3-methyltriazen-3-yl)-methyl]-methylamines: potential prodrugs for the cytotoxic monomethyltriazenes.

Manning HW, Cameron LM, LaFrance RJ, Vaughan K, Rajaraman R. Manning HW, et al. Among authors: vaughan k. Anticancer Drug Des. 1985 Oct;1(1):37-43. Anticancer Drug Des. 1985. PMID: 3870879

5

Triazene metabolism. IV. Derivatives of hydroxymethyltriazenes: potential prodrugs for the active metabolites of the anti-tumour triazene, DTIC.

Cameron LM, LaFrance RJ, Hemens CM, Vaughan K, Rajaraman R, Chubb DC, Goddard PM. Cameron LM, et al. Among authors: vaughan k. Anticancer Drug Des. 1985 Oct;1(1):27-36. Anticancer Drug Des. 1985. PMID: 3870878

6

Triazene metabolism. III. In vitro cytotoxicity towards M21 cells and in vivo antitumour activity of the proposed metabolites of the antitumour 1-aryl-3,3-dimethyltriazenes.

Kohlsmith DJ, Vaughan K, Luner SJ. Kohlsmith DJ, et al. Among authors: vaughan k. Can J Physiol Pharmacol. 1984 Apr;62(4):396-402. doi: 10.1139/y84-063. Can J Physiol Pharmacol. 1984. PMID: 6733585

7

Differential cytotoxicity and DNA-damaging effects produced in human cells of the Mer+ and Mer- phenotypes by a series of 1-aryl-3-alkyltriazenes.

Gibson NW, Hartley JA, LaFrance RJ, Vaughan K. Gibson NW, et al. Among authors: vaughan k. Cancer Res. 1986 Oct;46(10):4999-5003. Cancer Res. 1986. PMID: 3756860

8

Differential cytotoxicity and DNA-damaging effects produced in human cells of the Mer+ and Mer- phenotypes by a series of alkyltriazenylimidazoles.

Gibson NW, Hartley J, La France RJ, Vaughan K. Gibson NW, et al. Among authors: vaughan k. Carcinogenesis. 1986 Feb;7(2):259-65. doi: 10.1093/carcin/7.2.259. Carcinogenesis. 1986. PMID: 3948314

9

DNA sequence specificity of guanine N7-alkylations for a series of structurally related triazenes.

Hartley JA, Mattes WB, Vaughan K, Gibson NW. Hartley JA, et al. Among authors: vaughan k. Carcinogenesis. 1988 Apr;9(4):669-74. doi: 10.1093/carcin/9.4.669. Carcinogenesis. 1988. PMID: 2833369

10

alpha-Hydroxylated triazenes: potential active metabolites of anti-tumour dimethyltriazenes [proceedings].

Stevens MF, Gescher A, Hickman JA, Vaughan K, Simmonds RJ. Stevens MF, et al. Among authors: vaughan k. J Pharm Pharmacol. 1978 Dec;30 Suppl:48P. doi: 10.1111/j.2042-7158.1978.tb10755.x. J Pharm Pharmacol. 1978. PMID: 32304 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

307 results

Search Page

Filters